LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Dovitinib | 10.0 | uM | LJP5 | 3 | E19 | 72 | hr | 1657 | 2650 | 5505 | 0.4813 | 0.2579 |
| BT-20 | Enzastaurin | 10.0 | uM | LJP5 | 1 | D13 | 72 | hr | 1657 | 6679 | 5505 | 1.2131 | 1.3049 |
| BT-20 | Enzastaurin | 10.0 | uM | LJP5 | 2 | D13 | 72 | hr | 1657 | 6961 | 5505 | 1.2643 | 1.3782 |
| BT-20 | Enzastaurin | 10.0 | uM | LJP5 | 3 | D13 | 72 | hr | 1657 | 6961 | 5505 | 1.2643 | 1.3782 |
| BT-20 | Erlotinib | 10.0 | uM | LJP5 | 1 | M19 | 72 | hr | 1657 | 3642 | 5505 | 0.6615 | 0.5157 |
| BT-20 | Erlotinib | 10.0 | uM | LJP5 | 2 | M19 | 72 | hr | 1657 | 3691 | 5505 | 0.6704 | 0.5284 |
| BT-20 | Erlotinib | 10.0 | uM | LJP5 | 3 | M19 | 72 | hr | 1657 | 3227 | 5505 | 0.5861 | 0.4078 |
| BT-20 | Foretinib | 10.0 | uM | LJP5 | 1 | H07 | 72 | hr | 1657 | 1397 | 5505 | 0.2537 | -0.0678 |
| BT-20 | Foretinib | 10.0 | uM | LJP5 | 2 | H07 | 72 | hr | 1657 | 1516 | 5505 | 0.2754 | -0.0368 |
| BT-20 | Foretinib | 10.0 | uM | LJP5 | 3 | H07 | 72 | hr | 1657 | 1663 | 5505 | 0.3021 | 0.0014 |
| BT-20 | R406 | 10.0 | uM | LJP6 | 1 | C13 | 72 | hr | 1657 | 2543 | 5505 | 0.4619 | 0.2301 |
| BT-20 | R406 | 10.0 | uM | LJP6 | 2 | C13 | 72 | hr | 1657 | 2205 | 5505 | 0.4005 | 0.1422 |
| BT-20 | R406 | 10.0 | uM | LJP6 | 3 | C13 | 72 | hr | 1657 | 2641 | 5505 | 0.4797 | 0.2555 |
| BT-20 | Pictilisib | 10.0 | uM | LJP6 | 1 | D19 | 72 | hr | 1657 | 1377 | 5505 | 0.2501 | -0.0730 |
| BT-20 | Pictilisib | 10.0 | uM | LJP6 | 2 | D19 | 72 | hr | 1657 | 1685 | 5505 | 0.3061 | 0.0071 |
| BT-20 | Pictilisib | 10.0 | uM | LJP6 | 3 | D19 | 72 | hr | 1657 | 1600 | 5505 | 0.2906 | -0.0150 |
| BT-20 | Gefitinib | 10.0 | uM | LJP6 | 1 | N07 | 72 | hr | 1657 | 4241 | 5505 | 0.7703 | 0.6713 |
| BT-20 | Gefitinib | 10.0 | uM | LJP6 | 2 | N07 | 72 | hr | 1657 | 4334 | 5505 | 0.7872 | 0.6955 |
| BT-20 | Gefitinib | 10.0 | uM | LJP6 | 3 | N07 | 72 | hr | 1657 | 4267 | 5505 | 0.7750 | 0.6781 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP5 | 1 | O01 | 72 | hr | 1657 | 1220 | 5505 | 0.2216 | -0.1138 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP5 | 2 | O01 | 72 | hr | 1657 | 1436 | 5505 | 0.2608 | -0.0576 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP5 | 3 | O01 | 72 | hr | 1657 | 1417 | 5505 | 0.2574 | -0.0626 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP6 | 1 | O01 | 72 | hr | 1657 | 1339 | 5505 | 0.2432 | -0.0828 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP6 | 2 | O01 | 72 | hr | 1657 | 1263 | 5505 | 0.2294 | -0.1026 |
| BT-20 | Geldanamycin | 10.0 | uM | LJP6 | 3 | O01 | 72 | hr | 1657 | 1458 | 5505 | 0.2648 | -0.0519 |